Level of Expression of OB-R Short and Long Isoforms in AML and MDS
| Group . | Total Cases . | Long Isoform (No. of Positive Cases) . | Short Isoform (No. of Positive Cases) . |
|---|---|---|---|
| Newly diagnosed AML | 22 | 15 | 13 |
| Primary AML | 15 | 13 | 9 |
| Secondary AML3-150 | 7 | 2 | 4 |
| Refractory AML | 4 | 4 | 4 |
| APL | 10 | 10 | 10 |
| Recurrent AML | 13 | 13 | 13 |
| MDS | 6 | 3 | 4 |
| Group . | Total Cases . | Long Isoform (No. of Positive Cases) . | Short Isoform (No. of Positive Cases) . |
|---|---|---|---|
| Newly diagnosed AML | 22 | 15 | 13 |
| Primary AML | 15 | 13 | 9 |
| Secondary AML3-150 | 7 | 2 | 4 |
| Refractory AML | 4 | 4 | 4 |
| APL | 10 | 10 | 10 |
| Recurrent AML | 13 | 13 | 13 |
| MDS | 6 | 3 | 4 |
OB-R expression was determined by PCR using primers for the mRNAs of the long and short OB-R isoforms (see Materials and Methods).
Abbreviations: MDS, myelodysplastic syndrome; APL, acute promyelocytic leukemia.
Secondary AML includes patients with a history of MDS or chemotherapy-induced AML.